CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Dexcom G6 CGM +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05370612
NCT05370612N/ACompleted

Continuous Glucose Monitoring in Pregnant Patients With Type 2 Diabetes, a Mixed Methods Approach

University of Wisconsin, Madison·interventional·Posted May 11, 2022·Updated Mar 31, 2026

In Brief

A clinical study evaluating Dexcom G6 CGM and Participant Finger Stick Glucose Monitoring for Type2Diabetes and Pregnancy in Diabetic. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This study will assess differences in patient preferences and glucose control between continuous glucose monitoring and standard glucose checks in pregnant patients with Type 2 Diabetes. 40 participants will be on study for approximately 182 days (26 weeks).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
CollaboratorsDexCom, Inc.

Timeline

N/ACompletedFinished
2023202420252026
First PostedMay 11, 2022
Enrollment StartAug 8, 2022
Primary CompletionOct 6, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.1 years ago

Interventions

Dexcom G6 CGMdevice

Dexcom 6 CGM, an FDA approved device. Sensors will be placed on the abdomen per package instruction to collect continuous glucose data. Experimental Group will wear CGM for the duration of their pregnancy. Control Group will have CGM data collected for 10 days at enrollment and at 28-32 weeks into their pregnancy.

Participant Finger Stick Glucose Monitoringother

Standard of care for individual participant